- Home
- APLM vs MARPS Comparison
APLM vs MARPS Comparison
Compare APLM & MARPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLM
- MARPS
- Stock Information
- Founded
- APLM 2016
- MARPS 1956
- Country
- APLM United States
- MARPS United States
- Employees
- APLM N/A
- MARPS N/A
- Industry
- APLM Blank Checks
- MARPS Oil & Gas Production
- Sector
- APLM Finance
- MARPS Energy
- Exchange
- APLM Nasdaq
- MARPS Nasdaq
- Market Cap
- APLM 7.7M
- MARPS 7.8M
- IPO Year
- APLM N/A
- MARPS N/A
- Fundamental
- Price
- APLM $6.71
- MARPS $3.85
- Analyst Decision
- APLM Strong Buy
- MARPS
- Analyst Count
- APLM 2
- MARPS 0
- Target Price
- APLM $425.00
- MARPS N/A
- AVG Volume (30 Days)
- APLM 42.6K
- MARPS 2.1K
- Earning Date
- APLM 04-15-2025
- MARPS 01-01-0001
- Dividend Yield
- APLM N/A
- MARPS 8.50%
- EPS Growth
- APLM N/A
- MARPS N/A
- EPS
- APLM N/A
- MARPS 0.30
- Revenue
- APLM $2,101,000.00
- MARPS $945,496.00
- Revenue This Year
- APLM N/A
- MARPS N/A
- Revenue Next Year
- APLM N/A
- MARPS N/A
- P/E Ratio
- APLM N/A
- MARPS $13.05
- Revenue Growth
- APLM 70.54
- MARPS N/A
- 52 Week Low
- APLM $6.20
- MARPS $3.76
- 52 Week High
- APLM $63.00
- MARPS $6.50
- Technical
- Relative Strength Index (RSI)
- APLM 43.33
- MARPS 51.15
- Support Level
- APLM $6.20
- MARPS $3.85
- Resistance Level
- APLM $8.00
- MARPS $3.95
- Average True Range (ATR)
- APLM 1.37
- MARPS 0.03
- MACD
- APLM -0.18
- MARPS 0.01
- Stochastic Oscillator
- APLM 9.44
- MARPS 52.94
About APLM Apollomics Inc.
Apollomics Inc is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company lead programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.
About MARPS Marine Petroleum Trust Units of Beneficial Interest
Marine Petroleum Trust is a U.S based royalty trust. It provides administration and liquidation of rights to payments from oil and natural gas leases in the Gulf of Mexico. The Trust's subsidiary holds title to interests in properties which are situated offshore of Louisiana. The revenues of the trust are derived from the oil and natural gas production activities of third parties.